BioSpace News Archive

PTC Therapeutics, Inc. announced that on Feb. 15, 2024, the company approved non-statutory stock options to purchase an aggregate of 1,840 shares of its common stock and 4,275 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to six new employees.

Stevanato Group S.p.A. announced that it will issue financial results for the fourth quarter and year end of 2023 on Thursday, March 7, 2024, at 6:30 a.m.

Neuraptive Therapeutics, Inc., a pioneer in nerve repair and regeneration, is proud to announce new 24-week data from the ongoing NEUROFUSE Study for NTX-001, further solidifying the product’s status following the previously announced proof of concept results based on the 12-week data in January 2024.

Amarvir Gill (the “Acquiror”), the President, Chief Executive Officer and a Director of Biosenta Inc. (“Biosenta”) listed on the Canadian Securities Exchange (CSE: ZRO) announces that he acquired 1,250,000 common shares

Boston Scientific Corporation announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has priced a public offering of €750,000,000 aggregate principal amount of 3.375% notes due 2029 and €1,250,000,000 aggregate principal amount of 3.500% notes due 2032.

Immunofoco announced a significant milestone, that following the approval by the CDE in China for the clinical trial application of IMC001, an EpCAM-targeting autologous CAR-T cell product for infusion, it also received the IND approval from the U.S. FDA, for the treatment of EpCAM-positive advanced gastrointestinal tumors, including but not limited to advanced gastric cancer and gastroesophageal junction adenocarcinoma.

TC BioPharm PLC announced that the MHRA has officially accepted its proposed amendment to the Company’s clinical trial authorisation.

Biosenta Inc. (CSE: ZRO) (the “Company” or “Biosenta”), is pleased to announce that it has entered into debt settlement agreements with certain creditors, pursuant to which the Company

Qosina, a global supplier of OEM single-use components to the medical and biopharmaceutical industries, is pleased to introduce Pharma+™ tubing retainers to its extensive portfolio.

AtomVie Global Radiopharma Inc. (AtomVie), a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced strategic collaborations